Robust escalation of nicotine intake with extended access to nicotine self-administration and intermittent periods of abstinence

Neuropsychopharmacology

Volumn 37, Issue 9, 2012, Pages 2153-2160

  Cohen, Ami ^a   Koob, George F ^a   George, Olivier ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

addiction; dependence; monoamine oxidase; phenelzine; tobacco; withdrawal

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); NICOTINE; PHENELZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIGARETTE SMOKING; ENZYME INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ADDICTIVE; CONDITIONING, OPERANT; MALE; MONOAMINE OXIDASE INHIBITORS; NICOTINE; PHENELZINE; RATS; RATS, WISTAR; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 84863984846     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.67     Document Type: Article

References (48)

1. Ahmed SH, Koob GF (1998). Transition from moderate to excessive drug intake: change in hedonic set point. Science 282: 298-300.
2. Ahmed SH, Walker JR, Koob GF (2000). Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology 22: 413-421.
3. Ben-Shahar O, Ahmed SH, Koob GF, Ettenberg A (2004). The transition from controlled to compulsive drug use is associated with a loss of sensitization. Brain Res 995: 46-54.
4. Berlin I, Anthenelli RM (2001). Monoamine oxidases and tobacco smoking. Int J Neuropsychopharmacol 4: 33-42.
5. Conklin CA, Perkins KA, Sheidow AJ, Jones BL, Levine MD, Marcus MD (2005). The return to smoking: 1-year relapse trajectories among female smokers. Nicotine Tob Res 7: 533-540.
6. Cummings KM, Mahoney M (2006). Current and emerging treatment approaches for tobacco dependence. Curr Oncol Rep 8: 475-483.
7. Doubeni CA, Reed G, Difranza JR (2010). Early course of nicotine dependence in adolescent smokers. Pediatrics 125: 1127-1133.
8. Dougherty J, Miller D, Todd G, Kostenbauder HB (1981). Reinforcing and other behavioral effects of nicotine. Neurosci Biobehav Rev 5: 487-495.
9. Engelmann JM, Radke AK, Gewirtz JC (2009). Potentiated startle as a measure of the negative affective consequences of repeated exposure to nicotine in rats. Psychopharmacology (Berl) 207: 13-25.
10. Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998). Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393: 76-79.
11. Fowler JS, Logan J, Wang GJ, Volkow ND, Telang F, Zhu W et al (2003). Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci USA 100: 11600-11605.
12. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R et al (1996). Inhibition of monoamine oxidase B in the brains of smokers. Nature 379: 733-736.
13. George O, Ghozland S, Azar MR, Cottone P, Zorrilla EP, Parsons LH et al (2007). CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc Natl Acad Sci USA 104: 17198-17203.
14. Greenwell TN, Funk CK, Cottone P, Richardson HN, Chen SA, Rice KC et al (2009). Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long-, but not short-access rats. Addict Biol 14: 130-143.
15. Grunberg NE (1994). Overview: biological processes relevant to drugs of dependence. Addiction 89: 1443-1446.
16. Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M et al (2005). Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neurosci 25: 8593-8600.
17. Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M et al (2006). Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur J Neurosci 24: 3532-3540.
18. Heilig M, Koob GF (2007). A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30: 399-406.
19. Henningfield JE, Goldberg SR (1983). Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 19: 989-992.
20. Hughes JR, Higgins ST, Bickel WK (1994). Nicotine withdrawal vs other drug withdrawal syndromes: similarities and dissimilarities. Addiction 89: 1461-1470.
21. Irvine EE, Cheeta S, File SE (2001). Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacol Biochem Behav 68: 319-325.
22. Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL (2000). Nicotine blood levels and sublective craving for cigarettes. Pharmacol Biochem Behav 66: 553-558.
23. Kapelewski CH, Vandenbergh DJ, Klein LC (2011). Effect of the monoamine oxidase inhibition on rewarding effects of nicotine in rodents. Curr Drug Abuse Rev 4: 110-121.
24. Kenny PJ, Markou A (2006). Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology 31: 1203-1211.
25. Kim MJ, Fleming CB, Catalano RF (2009). Individual and social influences on progression to daily smoking during adolescence. Pediatrics 124: 895-902.
26. Kitamura O, Wee S, Specio SE, Koob GF, Pulvirenti L (2006). Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berl) 186: 48-53.
27. Koob GF (2010). The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res 1314: 3-14.
28. Koob GF, Le Moal M (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97-129.
29. Kozlowski LT, Wilkinson DA, Skinner W, Kent C, Franklin T, Pope M (1989). Comparing tobacco cigarette dependence with other drug dependencies: greater or equal 'difficulty quitting' and 'urges to use,' but less 'pleasure' from cigarettes. JAMA 261: 898-901.
30. LeSage MG, Burroughs D, Pentel PR (2006). Effects of nicotine withdrawal on performance under a progressive-ratio schedule of sucrose pellet delivery in rats. Pharmacol Biochem Behav 83: 585-591.
31. Lotfipour S, Arnold MM, Hogenkamp DJ, Gee KW, Belluzzi JD, Leslie FM (2011). The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition. Neuropharmacology 61: 95-104.
32. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA et al (1992). Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43: 779-784.
33. McManus DJ, Greenshaw AJ (1991). Differential effects of antidepressants on GABAB and b-adrenergic receptors in rat cerebral cortex. Biochem Pharmacol 42: 1525-1528.
34. O'Dell LE, Chen SA, Smith RT, Specio SE, Balster RL, Paterson NE et al (2007). Extended access to nicotine self-administration leads to dependence: circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther 320: 180-193.
35. O'Dell LE, Koob GF (2007). 'Nicotine deprivation effect' in rats with intermittent 23-hour access to intravenous nicotine selfadministration. Pharmacol Biochem Behav 86: 346-353.
36. Paterson NE, Markou A (2004). Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats. Psychopharmacology (Berl) 173: 64-72.
37. Peto R, Lopez AD, Boreham J, Thun M, Heath Jr C, Doll R (1996). Mortality from smoking worldwide. Br Med Bull 52: 12-21.
38. Pomerleau CS, Pomerleau OF (1992). Euphoriant effects of nicotine in smokers. Psychopharmacology (Berl) 108: 460-465.
39. Richardson NR, Roberts DCS (1996). Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11.
40. Risner ME, Goldberg SR (1983). A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion. J Pharmacol Exp Ther 224: 319-326.
41. Simms JA, Steensland P, Medina B, Abernathy KE, Chandler LJ, Wise R et al (2008). Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol Clin Exp Res 32: 1816-1823.
42. Solomon RL, Corbit JD (1973). An opponent-process theory of motivation: II. Cigarette addiction. J Abnorm Psychol 81: 158-171.
43. Stolerman IP, Jarvis MJ (1995). The scientific case that nicotine is addictive. Psychopharmacology (Berl) 117: 2-10; discussion, 14-20.
44. Torrijos RM, Glantz SA (2006). The US Public Health Service 'treating tobacco use and dependence clinical practice guidelines' as a legal standard of care. Tob Control 15: 447-451.
45. US Department of Health and Human Services (1988). The Health Consequences of Smoking: Nicotine Addiction. A Report of the Surgeon General, 1988 (DHHS Publication no. [CDC] 88-8406). Centers for Disease Control and Prevention, Office on Smoking and Health: Rockville.
46. Valentine JD, Hokanson JS, Matta SG, Sharp BM (1997). Selfadministration in rats allowed unlimited access to nicotine. Psychopharmacology (Berl) 133: 300-304.
47. Villégier AS, Blanc G, Glowinski J, Tassin JP (2003). Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors. Pharmacol Biochem Behav 76: 267-274.
48. Villégier AS, Salomon L, Granon S, Changeux JP, Belluzzi JD, Leslie FM et al (2006). Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine. Neuropsychopharmacology 31: 1704-1713.